Integra LifeSciences Hosts Investor Day 2017 New York City
December 11 2017 - 7:12AM
Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading
global medical technology company, today will host an Investor Day
meeting with analysts and institutional investors in New York City,
beginning at 8:00 a.m. EST. Members of Integra’s executive
leadership team will discuss the company’s financial performance
and outlook.
Highlights of today’s conference include:
• Reaffirming 2017 financial guidance as provided on
October 26, 2017, including:
- Full-year 2017 revenue in the range of $1.165 billion to $1.175
billion, which includes about 4% organic growth
- Full-year 2017 adjusted earnings per share in the range of
$1.83 to $1.87
• Providing 2018 preliminary revenue estimate in the
range of $1.46 billion to $1.48 billion, which includes about 5%
organic growth
• Reaffirming 2018 adjusted earnings per share in the
range of $2.25 to $2.35, consistent with preliminary estimates
provided on October 26, 2017
• Establishing five-year financial targets of
approximately $2 billion in revenue and an adjusted EBITDA margin
range of 28% to 30%
The company will host a livestream of the
presentation and conference materials are available through the
Investors section of Integra’s website at www.integralife.com. A
replay of the conference will be archived on the company
website.
About Integra LifeSciencesIntegra
LifeSciences (NASDAQ:IART) is dedicated to limiting uncertainty for
clinicians, so they can concentrate on providing the best patient
care. Integra offers innovative solutions, including leading
plastic and regenerative technologies, in specialty surgical
solutions and orthopedics and tissue technologies. For more
information, please visit www.integralife.com.
This news release and statements made at the upcoming conference
contain information that includes or is based on forward‐looking
statements within the meaning of the federal securities law that
are subject to various risks and uncertainties that could cause our
actual results to differ materially from those expressed or implied
in such statements. Such factors include, but are not limited to:
weakening of economic conditions that could adversely affect the
level of demand for our products; our ability to integrate
acquisitions; pricing pressures generally, including
cost‐containment measures that could adversely affect the price of
or demand for our products; difficulties or delays in
manufacturing; changes in foreign exchange markets; legislative and
regulatory actions; the difficulty of predicting the timing or
outcome of product development efforts and regulatory agency
approvals or actions, if any; changes in reimbursement level from
third‐party payors; a significant increase in product liability
claims; the impact of federal legislation to reform the United
States healthcare system; changes in financial markets; changes in
the competitive environment; and our ability to realize anticipated
operational and manufacturing efficiencies. Additional information
concerning these and other factors is contained in our filings with
the U.S. Securities and Exchange Commission, including our Annual
Report on Form 10‐K and Quarterly Reports on Form 10‐Q. These
forward-looking statements are made based upon our current
expectations and we undertake no duty to update them or any of the
information contained in this news release and the conference
materials.
Certain non-GAAP financial measures are included in this news
release and the conference materials. Unless otherwise noted, all
references to gross margin, SG&A, EBITDA and EPS refer to
adjusted measures. A reconciliation of these non-GAAP
financial measures to the most comparable GAAP measures is provided
in the appendix of the “Third Quarter 2017 Earnings Call
Presentation” available on our website, www.integralife.com.
Additionally, please refer to the Current Report on Form 8-K
that we filed on October 26, 2017, where we provide explanations
for why management believes that the presentation of these non-GAAP
financial measures provides useful information to investors
regarding Integra’s financial condition and results of
operations.
All references to “2017E” in this news release and the
conference materials represent the Company’s estimate for 2017 full
year results as provided in guidance on October 26, 2017. Where
ranges were given, the midpoint of the range or rounding to the
nearest full percentage is used in this release and the conference
materials.
Investor Relations: Michael BeaulieuDirector,
Investor Relations (609)
750-2827michael.beaulieu@integralife.com
Media Contact: Laurene Isip Senior Director,
Global Corporate Communications(609) 750
7984laurene.isip@integralife.com
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Aug 2024 to Sep 2024
Integra LifeSciences (NASDAQ:IART)
Historical Stock Chart
From Sep 2023 to Sep 2024